Anthem Biosciences reported its highest-ever quarterly revenue of ₹6,109 Mn in Q4FY26, a 26.4% YoY increase.
EBITDA surged 52.2% YoY to ₹3,184 Mn with margins expanding 600 bps to 48.1%, while PAT grew 129.8% to ₹1,898 Mn.
The FY26 performance showed 15% revenue growth and over 30% growth in both EBITDA (₹9,896 Mn) and PAT (₹5,918 Mn).
A ₹12,000 Mn greenfield expansion is underway, and an exceptional item of ₹244 Mn was booked for new labor codes.